| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| BPMC | Blueprint Medicines Corporation | $68.7 | $3.02B | Downtrend |
Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2)
https://seekingalpha.com/article/4200203-loxo-oncology-frying-pan-fire-part-2-2?source=feed_sector_healthcare
Aug 17, 2018 -
0
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap
https://seekingalpha.com/article/4178491-core-biotech-buys-17-positive-commentary-gene-therapy-first-swap?source=feed_tag_etf_portfolio_strategy
May 31, 2018 - FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.A clinical hold for CRISPR Therapeutics caused some concern but I p
0
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
https://seekingalpha.com/article/4176837-evelo-biosciences-ipo-undervalued-almost-40-percent-cash?source=feed_tag_ipo_analysis
May 24, 2018 - The company has $81.5 million in cash that will be shown in the balance sheet of the next quarterly report.Taking into account the new cash, the company is trading at 2.5x its cash per share.Peers are
0
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas
https://seekingalpha.com/article/4176184-core-biotech-buys-16-taking-advantage-weakness-add-conviction-ideas?source=feed_all_articles
May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
0
Institutional Top Ideas Series: Opaleye Management
https://seekingalpha.com/article/4174919-institutional-top-ideas-series-opaleye-management?source=feed_all_articles
May 17, 2018 - Opaleye Management is a smaller fund with exceptional performance of late.Their top two holdings are heavily weighted and they are capitalizing on the targeted oncology theme as well.I provide a brief
0
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
https://seekingalpha.com/article/4173708-jfs-core-biotech-buys-15-removal-key-overhang-buying-weakness-o-updates-adding-2-positions?source=feed_all_articles
May 14, 2018 - Although this series is focused on the long term I continue to be pleased with our performance so far.President Trump´s speech on drug prices removed a key overhang for biotech (please see my blog pos
0
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
https://seekingalpha.com/article/4171623-pushing-preclinical-wave-early-stage-biotech-ipos-tests-investor-risk-appetite?source=feed_tag_ipo_analysis
May 09, 2018 - Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical ev
0
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
https://seekingalpha.com/article/4170858-jfs-core-biotech-buys-14-introducing-final-2-positions-and-taking-advantage-weakness-o-space?source=feed_all_articles
May 07, 2018 - The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.President Trump´s drug pricing speech is expected soon a
0
Institutional Top Ideas Series: Orbimed Advisors
https://seekingalpha.com/article/4169731-institutional-top-ideas-series-orbimed-advisors?source=feed_all_articles
May 04, 2018 - Today's fund in the spotlight, Orbimed Advisors, is quite large and in the midst of a leadership transition. They avoid outsized bets (over 5% weighting) yet still post decent returns.I provide a brie
0
Blueprint Medicines 2018 Q1 - Results - Earnings Call Slides
https://seekingalpha.com/article/4168744-blueprint-medicines-2018-q1-results-earnings-call-slides?source=feed_sector_healthcare
May 02, 2018 - The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q1 earnings call.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| ARRY | Array BioPharma Inc. | NASDAQ | $13.73 | $2.91B |
| ASND | Ascendis Pharma A/S | NASDAQ | $68.28 | $2.87B |
| HZNP | Horizon Pharma plc | NASDAQ | $19.22 | $3.2B |
| EBS | Emergent Biosolutions, Inc. | NYSE | $64.89 | $3.25B |
| HRTX | Heron Therapeutics, Inc. | NASDAQ | $33.8 | $2.63B |